Ketamine Therapy in Saskatoon

Ketamine-assisted therapy is available in Saskatoon through Evolve Counselling and Wellness, ATMA CENA's Saskatchewan member clinic at 1022A 8th Street. Saskatoon's regulatory framework is more restrictive than Alberta's: under the College of Physicians and Surgeons of Saskatchewan (CPSS) January 2021 position document, all parenteral ketamine routes (IV, IM, subcutaneous) for off-label use must be administered in a CPSS-accredited Non-Hospital Treatment Facility. Saskatchewan has no publicly funded psychiatric ketamine program. Most Saskatoon patients pay out-of-pocket. This guide explains what's available, who qualifies, what it costs, and how to access care.

Key takeaways

• Saskatoon's ATMA CENA member clinic is Evolve Counselling and Wellness (1022A 8th Street).
• CPSS January 2021 guidance requires CPSS-accredited Non-Hospital Treatment Facility (NHTF) for all parenteral routes — more restrictive than Alberta's framework.
• Saskatchewan Health (provincial drug plan) does not cover ketamine for psychiatric use; Spravato is not on the formulary; Exception Drug Status pathway exists but is not standard for off-label psychiatric ketamine.
• Saskatchewan has no publicly funded psychiatric ketamine program (unlike Edmonton's Misericordia/Grey Nuns or Vancouver's UBC Hospital).

What is ketamine-assisted therapy?

Ketamine therapy uses sub-anaesthetic doses of ketamine — a Health Canada-approved anaesthetic — to treat conditions including treatment-resistant depression, PTSD, anxiety, OCD, and chronic pain. Health Canada has approved ketamine as an anaesthetic; psychiatric use is off-label, a legal and common practice in Canadian medicine. Spravato (intranasal esketamine) is Health Canada-approved specifically for treatment-resistant MDD as of May 2020.

When ketamine is paired with structured psychotherapy before, during, and after dosing, the treatment is called ketamine-assisted psychotherapy (KAP) or ketamine-assisted therapy (KAT). ATMA CENA's Saskatoon partner uses this model — preparation sessions, the dosing session itself, and integration sessions afterward. For the full mechanism breakdown, see What Is Ketamine Therapy?.

Patients in Saskatoon or Saskatchewan considering this treatment can book a free information call to discuss eligibility and the local access pathway.

How ketamine works in the brain

Ketamine acts on the brain's glutamate system through NMDA (N-methyl-D-aspartate) receptor antagonism, triggering a downstream surge of glutamate, AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor activation, and BDNF (brain-derived neurotrophic factor) release that stimulates synaptogenesis — the formation of new neural connections within 24 to 72 hours of a dose (Lullau et al., 2023). Conventional antidepressants take 4 to 6 weeks to act on serotonin and norepinephrine; ketamine can produce antidepressant effects within 2 to 72 hours of a single IV dose. The Canadian Network for Mood and Anxiety Treatments (CANMAT) places IV racemic ketamine as a third-line treatment for adults with treatment-resistant depression (TRD) (Swainson et al., 2021).

Evolve Counselling and Wellness — ATMA CENA's Saskatoon member clinic

Evolve operates as a member clinic within ATMA CENA's network. Hours and individual clinician profiles should be confirmed during the information call. The clinical model uses ATMA CENA's three-phase KAP structure — preparation, dosing, integration — coordinated between Evolve and ATMA CENA's medical team.

Saskatchewan's regulatory framework

Two regulatory layers govern Saskatoon ketamine clinics.

Federal — Health Canada. Ketamine is a Schedule I controlled substance under the Controlled Drugs and Substances Act, legally prescribed by physicians and nurse practitioners. Health Canada has approved ketamine as an anaesthetic; psychiatric use is off-label.

Provincial — CPSS January 2021 position document. The College of Physicians and Surgeons of Saskatchewan (CPSS) does not prohibit off-label ketamine but sets a stricter facility threshold than Alberta. Off-label parenteral ketamine — IV, intramuscular, and subcutaneous — for psychiatric or pain indications outside hospital or emergency settings may only be administered in a CPSS-accredited Non-Hospital Treatment Facility (NHTF) under Regulatory Bylaw 26.1. Sublingual, oral, and intranasal routes have no equivalent NHTF requirement.

The College of Registered Nurses of Saskatchewan (CRNS) updated its Prescribing Medication Guideline effective February 4, 2026; nurse practitioners and RN(AAP)s prescribing controlled substances must operate within their scope and federal Controlled Drugs and Substances regulations. The practical result for Saskatoon patients: facility accreditation and physician oversight requirements are robust here, and the provider landscape is comparatively narrow.

Saskatchewan public coverage and insurance

Saskatchewan Health Plan / Saskatchewan Drug Plan: Ketamine for psychiatric use is not publicly covered. Spravato is not on the standard provincial formulary. Exception Drug Status (EDS) requests are technically possible through the Drug Plan and Extended Benefits Branch but are not a standard pathway for off-label psychiatric ketamine.

Saskatchewan has no publicly funded psychiatric ketamine program. Edmonton's Misericordia/Grey Nuns hospital program (covered under AHCIP) and Vancouver's UBC Hospital program (covered under MSP) are exceptions in Canada. Royal University Hospital and the Dubé Centre handle inpatient mental health care including some intranasal ketamine for inpatients with TRD, but this is not an outpatient route.

Private insurance: Most private insurers cover Spravato with prior authorization for documented TRD; generic IV/IM/sublingual ketamine for psychiatric use is generally not covered. Plans differ — verify with your administrator. Note: Alberta Blue Cross's psychedelic-assisted therapy coverage (effective March 2024) does not extend to Saskatchewan residents.

WCB Saskatchewan: Reviews ketamine claims case-by-case; no formal listing equivalent to WCB Alberta or WSIB Ontario.

Veterans Affairs Canada: Covers ketamine as a non-formulary product for service-related TRD or chronic pain on a case-by-case basis.

The practical result: most Saskatoon patients pay out-of-pocket.

What does ketamine therapy cost in Saskatoon?

ATMA CENA's published KAT pricing applies across the network, including Evolve Saskatoon: KAT Psychedelic Pathway from CAD $1,585 + $795 per additional session; KAT Psycholytic Pathway from CAD $1,530 + $740 per additional session; customized programs CAD $2,325–$6,930. A non-refundable deposit of CAD $300 applies. Confirm specific figures during your information call.

For a full Canadian pricing breakdown, including IV competitor pricing in Saskatchewan (e.g., The Linden Medical Centre IV protocols at ~$525/session) and Spravato cost context, see Ketamine Therapy Cost in Canada.

Who is a candidate?

Most Canadian ketamine clinics use the following inclusion criteria:

• Adults 18 or older
• Diagnosis of TRD (failure of at least 2 adequate antidepressant trials), bipolar depression with mood-stabilizer coverage, PTSD, anxiety disorders, OCD, or chronic pain
• Medically stable; able to provide informed consent

Absolute contraindications: active psychosis, uncontrolled severe hypertension, severe cardiovascular disease, current pregnancy, anaphylactic reaction to ketamine, active manic episode. Relative contraindications: history of substance use disorder, severe personality disorder with marked instability, recent stroke, untreated severe sleep apnea, concurrent MAOIs or high-dose benzodiazepines.

For full eligibility detail, see How to Qualify for Ketamine Therapy in Canada.

Saskatoon's ketamine landscape

Saskatoon's private ketamine market is comparatively narrow. The Linden Medical Centre (200-149 Pacific Avenue, Saskatoon) is the city's other established provider — a CPSS-accredited NHTF offering IV ketamine for treatment-resistant depression, PTSD, and chronic pain at approximately $525 per session under anesthetist monitoring (medical-model IV without integrated psychotherapy). The Linden is led by Dr. Monika Hooper, a psychiatrist, and operates additional clinics in Edmonton and Prince Albert.

Royal University Hospital and the Dubé Centre handle inpatient mental health care, with some intranasal ketamine available to eligible inpatients led by Dr. Evyn Peters and the University of Saskatchewan team — but this is not accessible as an outpatient service.

The practical Saskatoon choice for a patient typically comes down to: medical-model IV at The Linden (~$525/session, anesthetist-monitored, no integrated psychotherapy) versus KAP-model integrated therapy at Evolve via coordinated care partnership ($1,530–$6,930 program range, includes preparation and integration). The right fit depends on diagnosis, prior treatment history, and whether bundled psychotherapy is part of what you want.

Local Saskatoon practical notes

• Population: ~330k metro
• Major hospitals: Royal University Hospital (academic), St. Paul's Hospital, Saskatoon City Hospital
• Health authority: Saskatchewan Health Authority (SHA)
• Transit: Saskatoon Transit (bus only); Evolve's Eighth Street location is bus-route accessible
• Winter sessions (November–March): plan extra travel time and snow conditions; the 24-hour no-driving rule post-session means a designated driver or rideshare is essential

Frequently asked questions

Where is ATMA CENA's Saskatoon clinic? Evolve Counselling and Wellness, 1022A 8th Street, Saskatoon, SK S7H 0R9. Phone +1-639-384-7674. Operates as ATMA CENA's Saskatchewan member clinic via the coordinated care partnership.

Is ketamine therapy legal in Saskatoon? Yes. Ketamine is legally prescribed by physicians and nurse practitioners under the CDSA. Off-label psychiatric use is permitted under Canadian off-label prescribing rules. CPSS January 2021 guidance requires CPSS-accredited NHTF for all parenteral routes (IV, IM, SQ); sublingual and oral routes have no equivalent facility restriction.

Does Saskatchewan Health cover ketamine therapy? No. The Saskatchewan Drug Plan does not cover ketamine for psychiatric use. Spravato is not on the standard formulary. Exception Drug Status requests are case-by-case and not a standard pathway. Saskatchewan has no publicly funded psychiatric ketamine program.

How much does ketamine therapy cost at Evolve? ATMA CENA's published KAT pricing applies: CAD $1,530–$6,930 depending on pathway and number of sessions, plus a CAD $300 non-refundable deposit. Confirm specific figures during your information call.

Do I need a doctor's referral? No. The ATMA CENA intake call accepts self-referrals. The clinical screening determines eligibility.

What conditions are treated? Treatment-resistant depression, MDD with suicidal ideation, bipolar depression (with mood-stabilizer coverage), PTSD, anxiety disorders, OCD, and chronic pain. Specific eligibility is determined at clinical assessment.

Can I drive after a ketamine session? No. Patients cannot drive for at least 24 hours after a session. Arrange a designated driver or rideshare.

What's the difference between Evolve via ATMA CENA and The Linden? Evolve via coordinated care uses the KAP model — preparation, dosing, and integration psychotherapy bundled. The Linden is a medical-model IV clinic without integrated psychotherapy. Both are legitimate; KAP is supported by 2017 RCT evidence showing that adding integration psychotherapy after the acute course extended antidepressant durability (Wilkinson et al., 2017).

Can my existing therapist work with ATMA CENA's network? Yes — through coordinated care model. Your therapist can remain the primary therapeutic relationship while ATMA CENA's network provides medical oversight and dosing infrastructure. Discuss with your therapist and ATMA CENA team during the information call.

Sources

1. ATMA CENA — Saskatoon Member Clinic (Evolve Counselling and Wellness): https://psychedelic.healthcare/
2. ATMA CENA — Psychedelic-Assisted Therapy (pricing): https://psychedelic.healthcare/
3. ATMA CENA — Find care near you: https://psychedelic.healthcare/find-care/
4. CPSS Saskatchewan — Off-label Ketamine Use Position (January 2021): https://www.cps.sk.ca/iMIS/Documents/For%20Physicians/Advisories%20and%20Positions/2021.01.19%20Ketamine%20off-label%20use%20CPSS%20position%20document.pdf
5. CPSS Saskatchewan — Non-Hospital Treatment Facility Program: https://www.cps.sk.ca/imis/web/Programs/Non-Hospital_Treatment_Facility/NHTF_Landing.aspx
6. Saskatchewan Drug Plan — Exception Drug Status: https://www.saskatchewan.ca/residents/health/prescription-drug-plans-and-health-coverage/extended-benefits-and-drug-plan/exception-drug-status
7. CRNS Prescribing Medication Guideline (February 2026): https://www.crns.ca/wp-content/uploads/2020/11/Guideline-for-Prescribing-Medication.pdf
8. Health Canada DPD — Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
9. Lullau APM, et al. (2023). Antidepressant mechanisms of ketamine. Front Neurosci. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1223145/full
10. Swainson J, et al. (2021). CANMAT racemic ketamine recommendations. Can J Psychiatry. https://pubmed.ncbi.nlm.nih.gov/33174760/
11. Wilkinson ST, et al. (2017). CBT after ketamine. Psychother Psychosom. https://pmc.ncbi.nlm.nih.gov/articles/PMC5516265/

Related articles in this cluster

• Ketamine Therapy in Canada
• What Is Ketamine Therapy?
• Ketamine Therapy Cost in Canada
• How to Qualify for Ketamine Therapy in Canada
• Ketamine Therapy for Depression
• Ketamine Therapy in Calgary
• Ketamine Therapy in Edmonton
• Ketamine Therapy in Winnipeg
• ATMA CENA Saskatoon member clinic
• Find care near you

Last updated: 2026-05-05